ATHERSYS, INC.

Basic Information

3201 CARNEGIE AVE
CLEVELAND, OH, 44115-2634

Company Profile

Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant unmet clinical need, and we are particularly focused on developing therapies in the regenerative medicine area.

Additional Details

Field Value
DUNS: 839321403
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Combinatorial Treatment of Acute Spinal Cord Injury with MultiStem Cell Therapy and Intracellular Sigma Peptide

    Amount: $212,796.00

    DESCRIPTION provided by applicant One out of every fifty people living in the United States suffers from some form of paralysis a total of almost million Americans This proposal outlines the tr ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for

    Amount: $865,500.00

    DESCRIPTION provided by applicant Cardiovascular disease CVD represents a significant unmet medical need with over million patients in the United States suffering from acute myocardial infarcti ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    Amount: $224,721.00

    DESCRIPTION (provided by applicant): This is a resubmission of a Phase I-Phase II Fast-Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome (ARDS). ...

    STTR Phase I 2014 Department of Health and Human Services
  4. Pediatrician Office Drug Prevention

    Amount: $330,000.00

    DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) represents a significant unmet medical need with over 1 million patients in the United States suffering from acute myocardial infarcti ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. Cell Based Therapy for Treatment of Traumatic Brain Injury

    Amount: $1,555,219.00

    DESCRIPTION (provided by applicant): Previously performed and published studies have demonstrated that MultiStem(R), Athersys' patented adult adherent stem cell product, modulates the inflammato ...

    SBIR Phase II 2013 Department of Health and Human Services
  6. Cell Based Therapy for Treatment of Traumatic Brain Injury

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): Previously performed and published studies have demonstrated that MultiStem(R), Athersys' patented adult adherent stem cell product, modulates the inflammato ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Optimization of the angiogenic potential of multipotent adult progenitor cells

    Amount: $99,302.00

    DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage. Loss of oxygen to these tissues can r ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

    Amount: $205,471.00

    DESCRIPTION: The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related ...

    STTR Phase II 2007 Department of Health and Human Services
  9. Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

    Amount: $136,500.00

    DESCRIPTION (provided by applicant): The emergence of technologies enabling isolation of adult stem cells has allowed evaluation of cell therapeutics for central nervous system disorders with a path ...

    STTR Phase I 2006 Department of Health and Human Services
  10. In-vitro generation of cardiomyocytes from MAPC

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The development and institution of stem cell and tissue engineering methodologies hold the potential to target many of the most significant cardiovascular diseases ...

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government